While non-del19 EGFR mutations, ‘short’ EML4-ALK fusions (mainly variant 3), and presence of TP53 co-mutations have all been linked to earlier systemic treatment failure in both EGFR+ and ALK+ NSCLC,53, 54, 55, 56 our results show that high-risk oncogene variants are more important that TP53 status for intracranial disease control (Table 2 and Supplementary Figure S1, available at https://doi.org/10.1016/j.esmoop.2021.100161). This evidence concerns the gene EML4 and non-small cell lung carcinoma.